Copyright
©2012 Baishideng.
World J Gastrointest Endosc. Sep 16, 2012; 4(9): 409-413
Published online Sep 16, 2012. doi: 10.4253/wjge.v4.i9.409
Published online Sep 16, 2012. doi: 10.4253/wjge.v4.i9.409
No. of patients | TNM stage (mean ± SD) | |
Total | 387 | |
Control group | 289 (74.6) | 2.57 ± 0.96 |
Antiplatelet group | 98 (25.4) | 2.27 ± 0.93 |
Aspirin | 65 | 2.19 ± 0.92 |
Clopidogrel | 17 | |
Ticlopidid | 6 | |
Dipyridamole | 4 | |
Dual therapy | 6 |
Antiplatelet group (n = 98) | Control group (n = 289) | |
Symptoms | ||
Anemia | 43 (43.8) | 104 (35.9) |
Blood loss per rectum | 28 (28.5) | 56 (19.3) |
Obstruction/perforation | 15 (15.3) | 66 (22.8) |
Altered bowel habits | 3 (3) | 29 (10) |
Non-specific symptoms | 4 (4) | 18 (6.2) |
Screening | 5 (5.1) | 16 (5.5) |
Distribution | ||
Right | 42 (42.8) | 116 (40.1) |
Left | 33 (33.6) | 104 (35.9) |
Rectum | 23 (23.4) | 69 (23.8) |
Antiplatelet group (n = 98) | Control group (n = 289) | P value | |
Stage I (1) | 24 (24.4) | 47 (16.2) | 0.0721 |
Stage II (2) | 32 (32.6) | 79 (27.3) | 0.3656 |
Stage III (3) | 34 (34.6) | 114 (39.3) | 0.4707 |
Stage IV (4) | 8 (8.1) | 49 (16.9) | 0.033 |
- Citation: Symeonidis D, Koukoulis G, Christodoulidis G, Mamaloudis I, Chatzinikolaou I, Tepetes K. Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastrointest Endosc 2012; 4(9): 409-413
- URL: https://www.wjgnet.com/1948-5190/full/v4/i9/409.htm
- DOI: https://dx.doi.org/10.4253/wjge.v4.i9.409